Pharma Needs to Look Internally for New Leadership
PharmExec
DECEMBER 8, 2022
Companies should search within to gain talent edge.
PharmExec
DECEMBER 8, 2022
Companies should search within to gain talent edge.
PM360
MARCH 24, 2023
We covered the first one by looking at Organizational Structures , today, let’s dive into the second which is the toughest, not just for pharma, but for the entire country: Diversity, Equity, and Inclusion (DE&I). When we look at DE&I in pharma, how well we are doing depends on who you ask. population.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 19, 2022
Emma Hyland, VP strategy, commercial content at Veeva Systems, tells us modular content is the most significant wave of innovation hitting the content world in life sciences, and rightly so because HCPs’ needs and expectations have changed. Don’t think about how it will be laid out or what it will look like.”.
European Pharmaceutical Review
MAY 2, 2023
the average duration to develop a new medicine is still around 10-15 years We know that the research and development (R&D) process behind developing new medicines is increasingly complex. 7 While this context is well known, we are yet to fully realise what an ideal R&D future looks like. 1,2 In the EU, an estimated 2.7
PM360
AUGUST 29, 2022
To do this, you need to understand yourself quite well too. Succeeding Internally. Except for ensuring appropriate firewalls, the consensus from the stage was it’s less about where the function sits or if it reports to the CEO and more about the fact that internal success hinges on cross-functional knowledge, trust, and influence.
Star OUTiCO
JULY 8, 2022
I’m passionate about medtech and keeping it distinct from pharma, so the opportunity to take on a leadership role for the whole division and manage a team of recruiters was too good to pass up. Are they happy, and doing what they need to be doing to deliver for the company and themselves? It’s great.
pharmaphorum
JANUARY 24, 2023
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
Let's personalize your content